These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11929710)

  • 21. Risk factors for survival and the development of hepatocellular carcinoma in patients with primary biliary cirrhosis.
    Tomiyama Y; Takenaka K; Kodama T; Kawanaka M; Sasaki K; Nishina S; Yoshioka N; Hara Y; Hino K
    Intern Med; 2013; 52(14):1553-9. PubMed ID: 23857086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aminoterminal propeptide of type III procollagen and hyaluronan in patients with primary biliary cirrhosis: markers of fibrosis in primary biliary cirrhosis.
    Remmel T; Remmel H; Salupere V
    J Gastroenterol Hepatol; 1996 Nov; 11(11):1016-20. PubMed ID: 8985819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of deferred or no treatment with ursodeoxycholic acid in patients with early primary biliary cholangitis.
    Tanaka A; Hirohara J; Nakano T; Yagi M; Namisaki T; Yoshiji H; Nakanuma Y; Takikawa H;
    Hepatol Res; 2018 Aug; 48(9):727-734. PubMed ID: 29405510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between serum soluble CD14 and IL-8 levels and clinical outcome in primary biliary cholangitis.
    Umemura T; Sekiguchi T; Joshita S; Yamazaki T; Fujimori N; Shibata S; Ichikawa Y; Komatsu M; Matsumoto A; Shums Z; Norman GL; Tanaka E; Ota M
    Liver Int; 2017 Jun; 37(6):897-905. PubMed ID: 27860118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group.
    Poupon RE; Eschwège E; Poupon R
    J Hepatol; 1990 Jul; 11(1):16-21. PubMed ID: 1975819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients.
    Corpechot C; Carrat F; Poupon R; Poupon RE
    Gastroenterology; 2002 Mar; 122(3):652-8. PubMed ID: 11874998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.
    Corpechot C; Carrat F; Bonnand AM; Poupon RE; Poupon R
    Hepatology; 2000 Dec; 32(6):1196-9. PubMed ID: 11093724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary biliary cirrhosis in Southern Israel: a 20 year follow up study.
    Delgado JS; Vodonos A; Delgado B; Jotkowitz A; Rosenthal A; Fich A; Novack V
    Eur J Intern Med; 2012 Dec; 23(8):e193-8. PubMed ID: 23022449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis.
    Yang F; Wang Q; Wang Z; Miao Q; Xiao X; Tang R; Chen X; Bian Z; Zhang H; Yang Y; Sheng L; Fang J; Qiu D; Krawitt EL; Gershwin ME; Ma X
    Clin Rev Allergy Immunol; 2016 Feb; 50(1):114-23. PubMed ID: 26411425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ursodeoxycholic acid in the therapy for primary biliary cirrhosis: effects on progression and prognosis.
    Leuschner U; Manns MP; Eisebitt R
    Z Gastroenterol; 2005 Sep; 43(9):1051-9. PubMed ID: 16142614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
    Dohmen K; Tanaka H; Haruno M
    Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A brief review on prognostic models of primary biliary cholangitis.
    Chen S; Duan W; You H; Jia J
    Hepatol Int; 2017 Sep; 11(5):412-418. PubMed ID: 28913620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of ursodeoxycholic acid in patients with primary biliary cirrhosis: sense or nonsense.
    Van Den Bogaert E; Francque S; Pelckmans P; Michielsen P
    Acta Gastroenterol Belg; 2003; 66(4):283-7. PubMed ID: 14989050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis.
    Verma A; Jazrawi RP; Ahmed HA; Davis T; Bland JM; Benson M; Orchard RT; Theodossi A; Maxwell JD; Northfield TC
    Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1069-76. PubMed ID: 10524634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis.
    Fujita K; Nomura T; Morishita A; Shi T; Oura K; Tani J; Kobara H; Tsutsui K; Himoto T; Masaki T
    J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31430975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group.
    Poupon RE; Bonnand AM; Chrétien Y; Poupon R
    Hepatology; 1999 Jun; 29(6):1668-71. PubMed ID: 10347106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
    Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
    Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis?
    Krzeski P; Zych W; Kraszewska E; Milewski B; Butruk E; Habior A
    Hepatology; 1999 Oct; 30(4):865-9. PubMed ID: 10498635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.